Ignite Creation Date:
2024-05-05 @ 7:02 PM
Last Modification Date:
2024-10-26 @ 9:42 AM
Study NCT ID:
NCT00599365
Status:
UNKNOWN
Last Update Posted:
2008-02-15
First Post:
2008-01-04
Brief Title:
Impact of CAMP in an Ambulatory Renal Clinic
Sponsor:
San Francisco Veterans Affairs Medical Center
Organization:
San Francisco Veterans Affairs Medical Center
Study Overview
Official Title:
Impact of a Pharmacists Collaborative Management Adherenceand Medication Education Program CAMP in an Ambulatory Renal Clinic
Status:
UNKNOWN
Status Verified Date:
2007-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAMP
Brief Summary:
The purpose of this study is to see if a pharmacist can help patients understand how heshe should be taking their medications The study is also being done to see if meeting with the pharmacist can help patients better control chronic kidney disease and the medical problems that can occur
Detailed Description:
Chronic kidney disease CKD is a serious condition associated with premature mortality decrease quality of life and increase health-care costs An estimated 19 million Americans 1 in 9 US adults have non-dialysis dependent CKD Stages 1-41 The health care expenditures for caring for patients with CKD are substantial According to Centers for Medicare and Medicaid Services CMS the estimated annual health cost per patient for managing patients with CKD is markedly higher 28000 compared to the costs for caring for diabetic patients 10000 per patient and heart failure patients 5000 per patient 2 According to the National Kidney Foundation as renal function declines the number of renal complications notably high blood pressure anemia malnutrition and mineral and bone disorders increases along with the severity A large proportion of patients with CKD also develop multiple co-morbidities particularly hypertension diabetes and hyperlipidemia Fortunately accumulating evidence indicates that treatment of earlier stages of chronic kidney disease can prevent the development of kidney failure Stage 53 In addition early prevention of cardiovascular risk factors in patients with CKD may reduce cardiovascular events before and after the onset of kidney failure3 Because many patients particularly in the later stages of CKD have multiple renal complications and chronic co-morbidities these patients are potentially at high risk of medication non-adherence and non-persistence defined as premature discontinuation of medication therapy Studies have demonstrated that patients with chronic diseases typically take only 50 of prescribed doses of medication leading to increased disease severity clinic visits and hospital admissions resulting in substantial healthcare expenditures45 In the United States alone the cost of illness due to non-adherence was estimated to be 170 billion per year6 In addition the associated total cost of treating the complications resulting from poor adherence in dialysis and transplant patients exceeds 950 million7 Potential barriers to medication adherence for patients with chronic diseases include but are not limited to complex medication regimens multiple drug doses treatment of asymptomatic conditions and cognitive factors Although not well-studied in pre-dialysis patients limited data suggests that important causes of medication non-adherence in chronic dialysis patients include inadequate prescription coverage or high medication costs lack of transportation and adverse effects 8
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| T0986 | None | None | None |